TICKERNERD
Menu
CYTKCYTKHealthcare · Biotechnology

CYTK Stock Forecast: Cytokinetics, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$61
−2.15% on the day

The 22 Wall Street analysts covering Cytokinetics, Inc. hold a median 12-month price target of $108 — +75.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 5 Oct 2026 — in the lower half.

Market cap
$9.1B
Ticker Nerd rank
49 / 100
Median analyst target
$108
Analysts covering
22
Revenue$28.6M−57.1% y/y
Operating income−$179.2M
Net income−$198.8M
Free cash flow−$164.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.5%
1M
−15.6%
YTD
−3.4%
1Y
+1.2%
From 52W high
−29.7%
From 52W low
+12.0%
$55
$87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CYTK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cytokinetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Oct 2026
49 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
88
Volatility
82
Momentum
71
Value
70
Accruals
47
Quality
45
Growth
32
Size
17
Issuance
10

Revisions (88): Analysts have, on balance, been raising their forecasts.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CYTK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CYTK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160Jan 26Apr 26Jul 26Oct 26CYTKHigh $146Median $108Low $85

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
20 Buy2 Hold0 Sell
Low $85Median $108High $146

The green dot is the last close — the median target sits +75.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
31 Aug 2026HC Wainwright & Co.ReiteratesBuy$140
13 Aug 2026BarclaysMaintainsOverweight$95 → $110
13 Aug 2026BarclaysMaintainsOverweight—
13 Aug 2026JP MorganMaintainsOverweight$97 → $103
13 Aug 2026JP MorganMaintainsOverweight—
10 Aug 2026Truist SecuritiesMaintainsBuy$106 → $112
10 Aug 2026Truist SecuritiesMaintainsBuy—
7 Aug 2026CitizensMaintainsMarket Outperform$105 → $110
7 Aug 2026CitizensMaintainsMarket Outperform—
7 Aug 2026NeedhamMaintainsBuy—
7 Aug 2026NeedhamMaintainsBuy$102 → $112
7 Aug 2026RBC CapitalMaintainsOutperform$117 → $112
7 Aug 2026RBC CapitalMaintainsOutperform—
7 July 2026RBC CapitalMaintainsOutperform$119 → $117
7 July 2026RBC CapitalMaintainsOutperform—
29 June 2026UBSUpgradeBuy—
24 June 2026MizuhoMaintainsOutperform—
17 June 2026NeedhamReiteratesBuy—
19 May 2026CitigroupInitiatesBuy—
12 May 2026JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CYTK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CYTK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Cytokinetics, Inc. returned +1.2% against +16.6% for the S&P 500, dividends included.

CYTK vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26CYTKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CYTK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
14
Analysts cutting
1
Fundamentals

Cytokinetics, Inc. (CYTK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.0×

Cheaper than 93% of US stocks

Price / sales
134.8×

Cheaper than 3% of US stocks

Price / book
−49.9×

Cheaper than 99% of US stocks

EV / EBITDA
−13.5×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
−57.1%

Higher than 5% of US stocks

Earnings growth (YoY)
−57.1%

Higher than 9% of US stocks

Gross margin
80.5%

Higher than 91% of US stocks

Operating margin
−626.0%

Higher than 7% of US stocks

Net margin
−372.5%

Higher than 1% of US stocks

Returns & dividend
Return on equity
119.0%

Higher than 97% of US stocks

Return on assets
−28.1%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cytokinetics, Inc. (CYTK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cytokinetics, Inc. has a market value of $9.1B and an enterprise value of $9.4B.

  • Revenue in the twelve months to 30 June 2026: $67.7M. The latest quarter shrank 57.1% year on year.

  • Net income over the same four quarters: −$894.0M, a −1321.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−7.22.

  • Free cash flow in the twelve months to 30 June 2026: −$580.7M.

  • Shares outstanding: 138.8M.

  • Trailing P/E: −10.0×; forward P/E: −14.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cytokinetics, Inc. employs 673 people — $101K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

CYTK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CYTKCytokinetics, Inc.$9.1B
49
ARWRArrowhead Pharmaceuticals, Inc.$8.7B
55
CAICaris Life Sciences, Inc.$8.6B
35
TGTXTG Therapeutics, Inc.$8.6B
68
PTGXProtagonist Therapeutics, Inc.$9.0B
97
AXSMAxsome Therapeutics, Inc.$9.1B
70
KYMRKymera Therapeutics, Inc.$9.1B
72

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cytokinetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CYTK news & analysis

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026

GlobeNewsWire · 2 Oct 2026neutral

Cytokinetics announced four upcoming presentations at the Heart Failure Society of America Annual Scientific Meeting 2026, including two Late Breaking Clinical Research presentations and two oral presentations, to be held in Phoenix, AZ from October 9-12, 2026.

Why it matters — CYTK watchers would care because the presentations could highlight new clinical data on the company's heart failure programs at a major scientific meeting.

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

GlobeNewsWire · 30 Sept 2026positive

Cytokinetics launched ASPEN-HCM, a multi-center prospective real-world study evaluating MYQORZO (aficamten) in symptomatic obstructive hypertrophic cardiomyopathy. The study will track real-world safety, clinical effectiveness, and healthcare resource impact of the drug in routine clinical practice.

Why it matters — The launch of a real-world study expands evidence generation for MYQORZO beyond clinical trials, which could support its broader adoption and commercial prospects in routine practice.

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference

MarketBeat · 25 Sept 2026neutral

Cytokinetics executives presented the company's commercial expansion plans, cardiovascular pipeline, and business-development priorities at a Bernstein investor symposium, with focus on the MYQORZO launch and clinical programs targeting multiple forms of heart failure.

Why it matters — The presentation gives Cytokinetics watchers insight into the company's commercial strategy for MYQORZO and the momentum of its heart failure pipeline.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 17 Sept 2026neutral

Cytokinetics announced that on September 15, 2026 it granted stock options for an aggregate of 52,834 common shares and 35,025 restricted stock units to 23 employees hired in August and September 2026, as a material inducement to their employment. The grants were made under Nasdaq Listing Rule 5635(c)(4).

Why it matters — CYTK watchers would care because the inducement grants reflect the company's ongoing hiring and talent retention activity, a routine corporate development for a company that uses equity compensation to attract employees.

FAQ

Frequently asked questions about CYTK stock

What is the CYTK stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Cytokinetics, Inc. have a median 12-month price target of $108, with estimates ranging from $85 to $146. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CYTK stock a buy right now?

Of the 22 analysts covering Cytokinetics, Inc., 20 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cytokinetics, Inc. 49 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CYTK?

As at 5 Oct 2026, Cytokinetics, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (88 of 100).

Will CYTK stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +75.2% from the last close, and Ticker Nerd's factor model ranks Cytokinetics, Inc. 49 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CYTK stock forecast for 2030?

No analyst covering Cytokinetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CYTK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $146 over the next 12 months.

How has CYTK stock performed over the past year?

Cytokinetics, Inc. returned +1.2% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cytokinetics, Inc. do?

Cytokinetics, Incorporated is a specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing medicines that target muscle biology. Its current work centers on therapies for cardiac muscle dysfunction, particularly heart conditions in which the heart’s contractile performance is compromised.

What is the latest news on CYTK?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026". Cytokinetics announced four upcoming presentations at the Heart Failure Society of America Annual Scientific Meeting 2026, including two Late Breaking Clinical Research presentations and two oral presentations, to be held in Phoenix, AZ from October 9-12, 2026.

Company

About Cytokinetics, Inc.

Cytokinetics, Incorporated is a specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing medicines that target muscle biology. Its current work centers on therapies for cardiac muscle dysfunction, particularly heart conditions in which the heart’s contractile performance is compromised. The company markets MYQORZO, an oral cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy, and is advancing additional drug candidates such as aficamten for broader hypertrophic cardiomyopathy use and omecamtiv mecarbil for heart failure. Cytokinetics also develops other muscle-directed candidates in clinical-stage programs, reflecting its emphasis on precision treatments for diseases affecting cardiac and skeletal muscle function. Headquartered in South San Francisco, California, Cytokinetics plays a specialized role in the biopharmaceutical market by focusing on muscle performance disorders within cardiovascular medicine.

CEO Mr. Robert I. Blum · 673 employees · United States · https://www.cytokinetics.com